Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A. Tournigand C, et al. Among authors: quinaux e. J Clin Oncol. 2004 Jan 15;22(2):229-37. doi: 10.1200/JCO.2004.05.113. Epub 2003 Dec 2. J Clin Oncol. 2004. PMID: 14657227 Corrected and republished. Clinical Trial.
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.
Meta-Analysis Group In Cancer; Lévy E, Piedbois P, Buyse M, Pignon JP, Rougier P, Ryan L, Hansen R, Zee B, Weinerman B, Pater J, Leichman C, Macdonald J, Benedetti J, Lokich J, Fryer J, Brufman G, Isacson R, Laplanche A, Quinaux E, Thirion P. Meta-Analysis Group In Cancer, et al. Among authors: quinaux e. J Clin Oncol. 1998 Nov;16(11):3537-41. doi: 10.1200/JCO.1998.16.11.3537. J Clin Oncol. 1998. PMID: 9817272
Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer.
de Gramont A, Buyse M, Abrahantes JC, Burzykowski T, Quinaux E, Cervantes A, Figer A, Lledo G, Flesch M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, André T, Tabah-Fisch I, Tournigand C. de Gramont A, et al. Among authors: quinaux e. J Clin Oncol. 2007 Aug 1;25(22):3224-9. doi: 10.1200/JCO.2006.10.4380. J Clin Oncol. 2007. PMID: 17664470 Clinical Trial.
Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.
André T, Quinaux E, Louvet C, Colin P, Gamelin E, Bouche O, Achille E, Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Lledo G, Raoul Y, Debrix I, Buyse M, de Gramont A. André T, et al. Among authors: quinaux e. J Clin Oncol. 2007 Aug 20;25(24):3732-8. doi: 10.1200/JCO.2007.12.2234. J Clin Oncol. 2007. PMID: 17704423 Clinical Trial.
Comparison of the levogyre and dextro-levogyre forms of leucovorin in a phase III trial of bimonthly LV5FU2 versus monthly 5-fluorouracil and high-dose leucovorin for patients with stage II and III colon cancer (GERCOR C96.1).
Baumgaertner I, Quinaux E, Khalil A, Louvet C, Buyse M, de Gramont A, André T; GERCOR Group. Baumgaertner I, et al. Among authors: quinaux e. Clin Colorectal Cancer. 2010 Apr;9(2):E5-10. doi: 10.3816/CCC.2010.n.027. Clin Colorectal Cancer. 2010. PMID: 20378497 Clinical Trial.
Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial.
Oakman C, Francis PA, Crown J, Quinaux E, Buyse M, De Azambuja E, Margeli Vila M, Andersson M, Nordenskjöld B, Jakesz R, Thürlimann B, Gutiérrez J, Harvey V, Punzalan L, Dell'orto P, Larsimont D, Steinberg I, Gelber RD, Piccart-Gebhart M, Viale G, Di Leo A. Oakman C, et al. Among authors: quinaux e. Ann Oncol. 2013 May;24(5):1203-11. doi: 10.1093/annonc/mds627. Epub 2013 Jan 4. Ann Oncol. 2013. PMID: 23293111 Free article. Clinical Trial.
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials.
Laporte S, Squifflet P, Baroux N, Fossella F, Georgoulias V, Pujol JL, Douillard JY, Kudoh S, Pignon JP, Quinaux E, Buyse M. Laporte S, et al. Among authors: quinaux e. BMJ Open. 2013 Mar 13;3(3):e001802. doi: 10.1136/bmjopen-2012-001802. BMJ Open. 2013. PMID: 23485717 Free PMC article.
A phase III adjuvant randomised trial of 6 cycles of 5-fluorouracil-epirubicine-cyclophosphamide (FEC100) versus 4 FEC 100 followed by 4 Taxol (FEC-T) in node positive breast cancer patients (Trial B2000).
Delbaldo C, Serin D, Mousseau M, Greget S, Audhuy B, Priou F, Berdah JF, Teissier E, Laplaige P, Zelek L, Quinaux E, Buyse M, Piedbois P; Association Européenne de Recherche en Oncologie (AERO). Delbaldo C, et al. Among authors: quinaux e. Eur J Cancer. 2014 Jan;50(1):23-30. doi: 10.1016/j.ejca.2013.09.023. Epub 2013 Oct 29. Eur J Cancer. 2014. PMID: 24183460 Clinical Trial.
31 results